Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807556 | 0.83 | CES2 (0.41) | CYP3A4TSHRCES2CES1TDP1 | |
| SCHEMBL841515 | 0.83 | CYP3A4 (0.48) | CYP3A4TSHRPIK3CAALDH1A1TDP1 | |
| SCHEMBL28542075 | 0.83 | CES2 (0.41) | CYP3A4TSHRPIK3CACES2CES1 | |
| SCHEMBL31470034 | 0.78 | CYP3A4 (0.36) | CYP3A4TSHRPIK3CACES2CES1 | |
| SCHEMBL31470029 | 0.78 | CYP3A4 (0.36) | CYP3A4TSHRPIK3CACES2CES1 | |
| SCHEMBL12197665 | 0.74 | GABRA1 (0.46) | CYP3A4TSHRCES2CES1HPGD | |
| SCHEMBL141144 | 0.74 | CYP3A4 (0.46) | CYP3A4TSHRPIK3CAALDH1A1TDP1 | |
| SCHEMBL8246278 | 0.74 | ACHE (0.50) | CYP3A4TSHRCES2CES1ALDH1A1 | |
| SCHEMBL10073173 | 0.74 | CD44 (0.52) | CYP3A4TSHRPIK3CAALDH1A1TDP1 | |
| SCHEMBL7765934 | 0.74 | CYP3A4 (0.40) | CYP3A4TSHRPIK3CAALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024091409-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4269405-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | Shanghai Kechow Pharma, Inc. (CN) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023125627-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LYNK PHARMACEUTICALS CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| WO-2022135470-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | 上海科州药物研发有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2021127404-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2014011429-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014011429-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20130203593-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203593-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130019348-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130019348-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130019348-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2013009791-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013009791-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2013-01-17 | — | — | WO | disclosed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | TYMS, TYMP, DHFR | CYP3A4 45/4885TSHR 2552/4885PIK3CA 977/4885 |
| US-20130203593-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | CYP19A1, CYP1A1, AR | CYP3A4 228/4885TSHR 446/4885PIK3CA 1403/4885 |
| US-20130019348-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | ACHE, DDT, CAT | CYP3A4 369/4885TSHR 2875/4885PIK3CA 891/4885 |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | CYP3A4 3201/4885TSHR 3595/4885PIK3CA 105/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | CYP3A4 853/4885TSHR 768/4885PIK3CA 2154/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | CYP3A4 1166/4885TSHR 3862/4885PIK3CA 37/4885 |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | CYP3A4 3201/4885TSHR 3595/4885PIK3CA 105/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | CYP3A4 3711/4885TSHR 4206/4885PIK3CA 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.